FTRE Fortrea Holdings Inc.
USHealthcareAs of 2026-07-10 16:00
Why FTRE matters now
Fortrea Holdings Inc. (FTRE) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.76 with +0.51% on the session and $1.68B in market capitalization; recent performance reads 1-month +11.67% and YTD -11.25%.
The latest financial table shown here is Q1 2026, with revenue of $636.5M, net income of $-23.6M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 13.1%.
The latest indexable market news headline is "Stocks Look Shaky, But This Sector is Booming (Biotech)" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $17.50; recent insider activity includes Russell Erin L filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.65
P/S
0.53
EV/EBITDA
-8.60
DCF Value
$-19.60
FCF Yield
13.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
16.0%
Operating Margin
-0.5%
Net Margin
-16.5%
ROE
-79.1%
ROA
-16.7%
ROIC
-0.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $636.5M | $-23.6M | $-0.26 |
| Q4 2025 | $660.5M | $-32.5M | $-0.36 |
| FY 2025 | $2.72B | $-986.2M | $-10.81 |
| Q3 2025 | $701.3M | $-15.9M | $-0.17 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$18.17
Target (Median)
$17.50
Target Range
$14.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.11
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.